Shanghai Yishi Pharmaceutical Technology

Shanghai Yishi Pharmaceutical Technology (Yishi Pharma) is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology and immunology. Founded in 2021 and headquartered in Shanghai, the company specializes in targeting the DNA damage response (DDR) pathway and synthetic lethality mechanisms to treat various cancers. Its lead candidate, YS-101, is a potent and selective USP1 inhibitor that received IND approval from the NMPA in late 2023 for the treatment of advanced solid tumors. Yishi Pharma leverages its deep expertise in medicinal chemistry and cancer biology to advance a pipeline of precision medicines aimed at addressing significant unmet medical needs. The company is supported by prominent venture capital investors, including Apricot Capital.